Biocryst Pharmaceuticals Inc., of Research Triangle Park, N.C., said the National Institute of Allergy and Infectious Diseases exercised additional options to conduct phase I studies in man and efficacy studies in nonhuman primates to test an intramuscular formulation of BCX4430, the company's lead compound in its antiviral program, as well as to assess effective dose ranges and dose schedules.